SIGN UP

top stories

NewAmsterdam aces Phase 3 trial, but investors are skeptical

1 hour ago

FDA updates label of 33-year-old cancer drug with new dose and warning

1 hour ago

Venrock adds $500M to healthcare investing strategy after outlining 10th fund in January

1 hour ago

When generative AI meets the FDA: First digital health adcomm kicks off discussion

3 hours ago

Latest

Most read

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

5 days ago

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

5 hours ago

23andMe inks new research partnership as it winds down internal drug development efforts

6 hours ago

Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development

9 hours ago

Pfizer taps oncology head Boshoff as Dolsten's chief scientific officer successor

10 hours ago

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

10 hours ago

see latest stream

People

Exclusive: Former Pfizer commercial chief Angela Hwang to join Flagship

10 hours ago

CSL Behring will close California office as part of shrinking ex vivo work

2 days ago

Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers

5 days ago

Financing

Former NCI director teams up with serial entrepreneur for $70M VC fund targeting 'super-early' science

Yesterday

Exclusive: Synapticure raises $25M for its approach to virtual neurodegenerative disease care

Yesterday

Atlas Venture targets $450M for 14th biotech fund, the same size as its 2022 raise

2 days ago

Startups

Pfizer partners with two more Flagship biotechs on obesity, cancer

10 hours ago

Novartis strikes radiopharma deal with Ratio worth up to $745M

2 days ago

Exclusive: Athena Countouriotis' Avenzo taps Shanghai biotech for ADC, adds new funds

2 days ago

Deals

Evotec gains on Halozyme's takeover proposal

5 days ago

European Commission seeks biopharma feedback on Novo-Catalent deal — report

6 days ago

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

6 days ago

In FocusSee all

Lawmakers are poking holes in pharma's favorite new way to market medicines

Yesterday

A rare neurological disease is Sage’s last, best hope after failures in depression

2 days ago

Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder

Last week

Biotech industry worries over potential for RFK Jr. ally as FDA pick

2 weeks ago

Endpoints Standouts

How the world's biggest pharma and biotech companies paid their typical worker in 2023

4 months ago

In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024

4 months ago

Biopharma leaders charting a path for the industry's LGBTQ+ community

4 months ago

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

5 months ago

Peer review See all

Nov

15

ALX Oncology hires Genentech, Mirati vet as CMO; After Carmot, Heather Turner has three new roles on tap

Nov

8

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Nov

1

Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure

Oct

25

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson

Oct

18

Exclusive: Ex-Affimed CEO heads to UK nanomedicine biotech; Jami Rubin leaves Boundless Bio after IPO

Pharma channel feed

Yesterday

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

GSK’s linerixibat helped reduce itch in patients with an autoimmune liver disease that affects the bile ducts, meeting its primary endpoint in a late-stage trial.

READ MORE

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

Yesterday

FDA rejects Astellas’ effort to support longer use of eye drug Izervay

Yesterday

latest in Pharma

Ahead of adcomm, FDA raises safety questions for AstraZeneca’s reversal agent for life-threatening bleeds

Yesterday

BeiGene settles final suit over future Brukinsa generics

Yesterday

Drugmakers 'not doing everything that they could' to widen global access, new report finds

Yesterday

Merck finally has subcutaneous Keytruda results, and it's going to regulators

Yesterday

Syndax's Revuforj wins FDA approval in aggressive form of leukemia

2 days ago

see latest stories

Marketing channel feed

6 days ago

FDA says Merz's social media promotion with Nate Berkus is 'misleading'

Merz Pharmaceuticals landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was “false or misleading." Now the company is trying to smooth ...

READ MORE

Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine

Last month

UK watchdog criticizes Moderna for Covid-19 trial's use of WhatsApp to dangle payments to children

Last month

latest in Marketing

FDA criticizes AbbVie's 'misleading' ad with Serena Williams

2 months ago

Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra

3 months ago

RSV market pressure leads to slower launch for Moderna's vaccine

3 months ago

Verona inks financing deal worth up to $650M ahead of COPD decision

6 months ago

From the editor: Our final edition of Endpoints MarketingRx

6 months ago

see latest stories

FDA+ channel feed

Yesterday

Chinese drugmaker receives FDA warning letter after management hindered inspection

The FDA handed Chinese pharmaceutical company Tianjin Darentang Jingwanhong Pharmaceutical a warning letter after it removed information from translated manufacturing records and refused to ...

READ MORE

FDA offers more guidance on developing cell and gene therapies

2 days ago

Eli Lilly sues the US government over its proposed 340B rebate model

5 days ago

latest in FDA+

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

6 days ago

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

6 days ago

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

6 days ago

Drug inspector attrition leads to 'many fewer' checks than 2016 peak, GAO says

Last week

Intercept is denied full FDA approval for Ocaliva, but claims it will keep drug on market

Last week

see latest stories

Manufacturing channel feed

6 days ago

Lonza expands bioconjugates factory; WuXi Bio adds capacity in Germany

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

READ MORE

Novo Nordisk to phase out its production of human insulin pens globally

6 days ago

Merck KGaA’s life science unit is still feeling the Covid demand decline

6 days ago

latest in Manufacturing

Otsuka and ICU Medical forge IV manufacturing network to supply the US

Last week

AstraZeneca budgets another $2B to boost manufacturing and R&D in US

Last week

Thermo Fisher consolidates viral vector work in Massachusetts, cuts 160 workers

Last week

FDA records request lands Chinese API manufacturer on blocked import list

Last week

Coherus restarts biosimilar supply after delays; Novavax ends Covid vaccine deal with UK

Last week

see latest stories